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ABSTRACT
The purpose of this meta-analysis was to provide updated pooled
effect sizes of evidence-based psychotherapies and medications
for generalized anxiety disorder (GAD) and to investigate potential
moderators of outcomes. Seventy-nine randomized controlled
trials (RCT) including 11,002 participants with a diagnosis of GAD
were included in a meta-analysis that tested the efficacy of psy-
chotherapies or medications for GAD. Psychotherapy showed a
medium to large effect size (g = 0.76) and medication showed a
small effect size (g = 0.38) on GAD outcomes. Psychotherapy also
showed a medium effect on depression outcomes (g = 0.64) as did
medications (g = 0.59). Younger age was associated with a larger
effect size for psychotherapy (p < 0.05). There was evidence of
publication bias in psychotherapy studies. This analysis found a
medium to large effect for empirically supported psychotherapy
interventions on GAD outcomes and a small effect for medications
on GAD outcomes. Both groups showed a medium effect on
depression outcomes. Because medication studies had more pla-
cebo control conditions than inactive conditions compared to
psychotherapy studies, effect sizes between the domains should
not be compared directly. Patient age should be further investi-
gated as a potential moderator in psychotherapy outcomes in
GAD.
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Generalized anxiety disorder (GAD) is characterized by worry about a number of events
or activities that is excessive and difficult to control (American Psychiatric Association,
CONTACT Emily Carl emilycarl@utexas.edu Department of Psychology, University of Texas at Austin, 305
E. 23rd St., CLA 4.602, Austin, TX 78712, USA
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2013). GAD is relatively common, with an estimated lifetime prevalence of 4.3% in the
general population (Kessler, Petukhova, Sampson, Zaslavsky, & Wittchen, 2012), and
associated with marked impairment in role functioning and social life to a degree
equivalent to major depression (Kessler, DuPont, Berglund, & Wittchen, 1999), as well
as impairments in psychosocial functioning, role functioning, work productivity, and
health-related quality of life (Revicki et al., 2012). GAD is also associated with increased
health care utilization and medical costs. Marciniak et al. (2005) found that the total
lifetime medical cost for individuals with any anxiety disorder was US$6475, and that a
diagnosis of GAD was associated with an additional US$2138 total cost. Furthermore,
there is evidence that GAD is associated with utilizing emergency departments as much as
twice as often as patients with another Axis I diagnosis (Jones, Ames, Jeffries, Scarinci, &
Brantley, 2001). Given the high cost and adverse outcomes associated with GAD, an
updated critical comparison of the numerous available treatments is necessary.
Evidence-based psychotherapies have shown large effect sizes on GAD outcomes
(Hedges’ g = 0.80; Cuijpers, Cristea, Karyotaki, Reijnders, & Huibers, 2016). Research
has also supported the utility of pharmacological interventions for GAD. Specifically, a
meta-analysis of 21 placebo-controlled studies yielded a small effect size (d = 0.39;
Hidalgo, Tupler, & Davidson, 2007). Since these dates, new randomized controlled
trials (RCT) are available for both psychotherapies and pharmacological interventions.
Thus, there is a need to update the pooled effect sizes to reflect the addition of these
trials to better understand the effects of these interventions on GAD.
Moreover, there are several candidates for moderators of GAD treatment outcomes.
For example, there is some evidence that older age might lead to worse GAD treatment
outcomes (Gonçalves & Byrne, 2012; Gould, Coulson, & Howard, 2012; Hendriks, Oude
Voshaar, Keijsers, Hoogduin, & Van Balkom, 2008; Pinquart & Duberstein, 2007;
Wetherell et al., 2013). Next, the prognostic effect of comorbid disorders on GAD out-
comes is unclear, with some evidence that comorbidity is indicative of worse prognosis
(Bruce et al., 2005) and some evidence that comorbidity in GAD is associated with larger
treatment gains (Newman, Przeworski, Fisher, & Borkovec, 2010). A recent systematic
review investigated a large number of potential treatment moderators of treatment for
anxiety disorders and found little evidence for demographic variables, baseline symptom
severity, or comorbidity as moderators (Schneider, Arch, & Wolitzky-Taylor, 2015).
However, this study was not specific to GAD, only included 24 studies that compared at
least two active treatments, and did not employ meta-analytic techniques.
The present investigation employed a meta-analytic approach to compare the effect of
evidence-based psychotherapies and pharmacotherapy to control conditions. Both primary
GAD outcomes and secondary depression outcomes were compared, and follow-up data
were examined when available. We also explored a number of plausible moderators,
including demographic variables (e.g. age, percent female), clinical variables (e.g. pretreat-
ment severity, percent comorbid), and study variables (e.g. control type). Based on the extant
literature, we hypothesized that psychotherapy would show a large effect size compared to
waitlist and pill placebo conditions and a small effect size compared to treatment as usual or
psychological control conditions (Cuijpers et al., 2016). We also hypothesized that medica-
tion would show a small effect size compared to controls (Hidalgo et al., 2007).
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Method
Study selection
We selected RCT of both psychological and pharmacological treatment for GAD using
a comprehensive search strategy. We searched the following databases: PsycINFO,
PubMed, EBSCO, Web of Science, and Cochrane database of systematic reviews. We
searched for articles on psychotherapy and pharmacotherapy for GAD from up until
June 2017. The searches included the following terms: “cognitive behavioral, ” “cogni-
tive behavioral therapy,” “acceptance and commitment therapy,” “worry exposure,”
“psychotherapy,” “pharmacotherapy,” “pharmacology,” “SSRIs,” OR “benzodiazepines,”
in addition to “clinical trial” or “trial” alone; and in combination with “generalized
anxiety disorder,” or “GAD.” These words were searched as key words, title, abstract,
and Medical Subject Headings. We also examined citation maps and used the “cited by”
search tools. These findings were cross-referenced with references from reviews. We
included articles found in two existing meta-analyses examining CBT for GAD
(Cuijpers et al., 2016) and pharmacotherapy for GAD (Hidalgo et al., 2007). Lastly,
we asked colleagues from the United States of America and the Netherlands to identify
any RCT for GAD that we had left out. These initial search strategies produced 846
potential articles. Examination of the abstracts identified 79 articles that met all inclu-
sion criteria. The study selection process is depicted in Figure 1.
Inclusion criteria were as follows: (a) participants who met full DSM-III-R, DSM-IV,
DSM-IV-TR, or DSM-5 criteria for GAD; (b) empirically supported psychotherapy,
including cognitive-behavioral therapy, acceptance-based behavior therapy, applied
relaxation, worry exposure, etc.; or empirically supported pharmacotherapy, including
SSRIs, benzodiazepines, and other anxiolytics; (c) included a waitlist, treatment as usual, or
pill placebo or psychological placebo control condition; and (d) studies that used validated
measures of generalized anxiety. Studies meeting the following exclusion criteria were not
selected for the current meta-analysis: (a) single case studies; (b) treatment conditions
based on augmentation of psychological treatment; (c) studies of relapse prevention; (d)
studies only treating patients who showed a response to the treatment; (e) studies with
insufficient data unless study authors were able to provide such data; (f) studies with
redundant data; and (g) studies on children. Studies were also imported from the extant
meta-analyses (Cuijpers et al., 2016; Hidalgo et al., 2007). Of the 234 studies screened, 155
were excluded. Seventy-seven did not report on a GAD group specifically and four did not
diagnose GAD according to the DSM-III-R, DSM-IV, DSM-IV-TR, or DSM-V. Sixty-one
were not RCT. Thirty-eight had missing data; we attempted to contact the authors of these
studies but were unable to either receive a response or obtain the relevant data. Twenty-
eight studies did not provide a sufficient control condition. Twenty-two studies recruited
nonresponders to treatment or relapse prevention. Four studies were excluded for a child
population. In total, 79 studies with 11,002 participants met the final inclusion criteria and
were included in the meta-analysis. Study characteristics are presented in Table 1.
Software
Analyses were completed with Comprehensive Meta-Analysis version 3.3070 (CMA;
Biostat, 2014).
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Procedure
The primary outcome was reduction of GAD symptoms. The Hamilton Anxiety Rating
Scale (HAM-A; Hamilton, 1959), Penn State Worry Questionnaire (PSWQ; Meyer,
Miller, Metzger, & Borkovec, 1990) and Penn State Worry Questionnaire—
Abbreviated version (PSWQ-A; Hopko et al., 2003), Beck Anxiety Inventory (Beck,
Epstein, Brown, & Steer, 1988), and State-Trait Anxiety Inventory—Trait (STAI-T;
Spielberger, Gorsuch, & Lushene, 1970) captured generalized anxiety outcome in all
studies. Outcome data from the above measures were combined from each study using
every measure available. The secondary outcome of this analysis was depression symp-
toms. Studies with multiple primary or secondary outcome measures had outcomes
combined in the respective domain. Combined measures were given equal weight.
Table 2 provides a complete list of included outcome measures.
Data on the following variables were also collected: treatment protocol (e.g. CBT,
sertraline), treatment dose (i.e. number of sessions and/or medication dosage), year of
publication, study quality (allocation sequence, concealment of allocation to conditions,






































Additional records identified 
treeing through the literature 
(n = 49)
Records after duplicates removed 
(n = 812) 
Records screened 
(n =  812) 
Excluded due to  
treatment irrelevance 
(n = 578) 
Full-text articles screened 
for eligibility 
(n =  234)
Excluded due to:* 
Not Exclusively GAD (n = 77) 
Not an RCT (n = 61) 
Not enough data (n = 38) 
No control (n = 28) 
Only nonresponders/relapse 
prevention (n = 22) 
Not diagnosed GAD (n = 4) 
Not adult population (n = 4)
*some studies violated more than one.
Studies included in 
quantitative synthesis 
(meta-analysis) 
(n =  79) 
Figure 1. Flowchart of inclusion of studies.
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Table 1. Study characteristics.
Authors Year N1 Primary measure(s)
Secondary measure
(s) Primary outcome2
Alaka et al. 2014 291 HAM-A Duloxetine > PP
Aliyev et al. 2008 74 HAM-A Depakine-chrono > PP
Allgulander et al. 2001 268
260
261
HAM-A Venlafaxine (37.5 mg) > PP
Venlafaxine (75 mg) > PP
Venlafaxine (150 mg) > PP
Allgulander et al. 2004 370 HAM-A MADRS Sertraline > PP
Bakhsani et al. 2007 13
13
BAI, HAM-A Diazepam + tricyclic
antidepressant > PP
CBT > PP
Ball et al. 2015 226 HAM-A Duloxetine > PP
Barlow et al. 1992 23
20
21
HAM-A, STAI-T BDI, HAM-D CT > WL
Relaxation > WL
CT + relaxation > WL
Bidzan et al. 2012 254 HAM-A Vortioxetine > PP
Bonne et al. 2003 44 HAM-A, STAI-T BDI, HAM-D Homeopathic > PP
Borkovec et al. 1987 30 HAM-A, STAI-T HAM-D CT > Psych PL
Borkovec et al. 1993 36
38
HAM-A, PSWQ, STAI-T BDI, HAM-D AR > Psych PL
CBT > Psych PL
Bowman et al. 1997 35 HAM-A, STAI-T Self-examination therapy > WL
Brawman-Mintzer et
al.
2006 326 HAM-A MADRS Sertraline > PP
Brenes et al. 2015 118 HAM-A, PSWQ BDI Telephone CBT > Psych PL
Butler et al. 1991 37
38
BAI, HAM-A, STAI-T BDI BT > WL
CBT > WL
Connor et al. 2002 35 HAM-A Kava kava < PP
Dahlin et al. 2016 85 BAI, PSWQ MADRS, PHQ-9 Internet acceptance BT > WL
Darcis et al. 1995 110 HAM-A Hydroxyzine > PP
Davidson et al. 1999 191
185
185
HAM-A Buspirone > PP
Venlafaxine (75 mg) > PP
Venlafaxine(150 mg) > PP
Davidson et al. 2004 307 HAM-A HAM-D Escitalopram > PP
Davidson et al. 2008 70 HAM-A Duloxetine > PP
Dugas et al. 2003 52 BAI, PSWQ BDI Group CBT > WL
Dugas et al. 2010 42
43
PSWQ, STAI-T BDI-II AR > WL
CBT > WL




BAI, HAM-A, STAI-T BDI Analytic therapy high
contact < Psych PL
Analytic therapy low contact < Psych
PL
CT high contact > Psych PL
CT low contact > Psych PL
Feltner et al. 2003 130
135
127
HAM-A HAM-D Lorazepam > PP
Pregbalin (150 mg) > PP
Pregbalin (600 mg) > PP
Gelenberg et al. 2000 238 HAM-A Venlafaxine > PP
Gommoll et al. 2015 444
444
HAM-A HAM-D Vilazodone (20 mg) > PP
Vilazodone (40 mg) > PP
Hackett et al. 2003 186
288
276
HAM-A Diazepam > PP
Venlafaxine (75 mg) > PP
Venlafaxine (150 mg) > PP
Hartford et al. 2007 323
325
HAM-A Duloxetine > PP
Venlafaxine > PP
Hoge et al. 2013 89 BAI, HAM-A MBSR > Psych PL
Hoyer et al. 2009 57
58
HAM-A, PSWQ, STAI-T BDI, HAM-D AR > WL
Worry exposure > WL
Johnston et al. 2011 85
88
PSWQ PHQ-9 Clinician-guided iCBT > WL
Coach-guided iCBT > WL
Jones et al. 2016 41 PSWQ-A PHQ-9 iCBT > WL
Kasper et al. 2009 249
253
HAM-A HAM-D Pregbalin > PP
Venlafaxine > PP
Koszycki et al. 2010 22 BAI, HAM-A, PSWQ BDI CBT > Psych PL
(Continued)
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Table 1. (Continued).
Authors Year N1 Primary measure(s)
Secondary measure
(s) Primary outcome2
Lader et al. 1998 163
162
HAM-A MADRS Buspirone > PP
Hydroxyzine > PP
Ladoucer et al. 2000 26 BAI, PSWQ BDI CBT > WL
Leichsenring et al. 2009 57 BAI, HAM-A, PSWQ,
STAI-T
BDI CBT > Psych PL
Lenze et al. 2009 177 HAM-A, PSWQ HAM-D Escitalopram > PP
Levy Berg et al. 2009 61 BAI Affect-Focused Psychotherapy > TAU
Linden et al. 2005 72
72
HAM-A, STAI-T CBT Group A > Psych PL
CBT Group B > Psych PL







HAM-A Duloxetine > PP
Vortioxetine (2.5 mg) > PP
Vortioxetine (5 mg) > PP
Vortioxetine (10 mg) > PP
Mohlman et al. a 2003 15 STAI-T BDI Enhanced CBT > WL
Mohlman et al. b 2003 21 BAI BDI Standard CBT > WL
Moller et al. 2001 207
205
HAM-A HAM-D Alprazolam > PP
Opipramol > PP
Montgomery et al. 2006 266 HAM-A HAM-D Pregbalin > PP
Pande et al. 2003 126
132
132
HAM-A HAM-D Lorazepam > PP
Pregbalin (150 mg) > PP
Pregbalin (600 mg) > PP
Park et al. 2014 94
95
HAM-A, PSWQ, STAI-T BDI Gamisoyo-San (Individual) > PP
Gamisoyo-San (Multi-
Compound) > PP
Paxling et al. 2011 82 BAI, PSWQ, STAI-T BDI, MADRS iCBT > WL
Pollack et al. 2001 324 HAM-A Paroxetine > PP
Pollack et al. a 2008 425
420
421
HAM-A Tiagbine (4 mg) > PP
Tiagbine (8 mg) > PP
Tiagbine (12 mg) > PP
Pollack et al. b 2008 441 HAM-A Tiagbine > PP
Pollack et al. c 2008 438 HAM-A Tiagbine > PP
Power et al. 1990 21
21
HAM-A CBT > PP
Diazepam > PP
Power et al. 1990 40
40
HAM-A CBT > PP
Diazepam > PP
Rezvan et al. 2008 24
24
PSWQ CBT > WL
CBT + IPT > WL
Rickels et al. 2000 182
177
182
HAM-A Venlafaxine (75 mg) > PP
Venlafaxine (150 mg) > PP
Venlafaxine (225 mg) > PP
Rickels et al. 2003 368
377
HAM-A Paroxetine (20 mg) > PP
Paroxetine (40 mg) > PP




HAM-A HAM-D Alprazolam > PP
Pregbalin (300 mg) > PP
Pregbalin (450 mg) > PP
Pregbalin (600 mg) > PP
Robinson et al. 2010 95
98
PSWQ PHQ-9 Clinician-guided iCBT > WL
Technician-guided iCBT > WL
Roemer et al. 2008 31 PSWQ BDI ACT > WL
Rothschild et al. 2012 289 HAM-A Vortioxetine < PP
Sarris et al. 2013 58 BAI, HAM-A Kava kava > PP
Stanley et al. 1996 31 HAM-A, PSWQ, STAI-T HAM-D CBT < Psych PL
Stanley et al. a 2003 64 HAM-A, PSWQ, STAI-T BDI, HAM-D CBT > Psych PL
Stanley et al. b 2003 9 BAI, PSWQ BDI CBT > TAU
Stanley et al. 2009 134 HAM-A, PSWQ BDI-II CBT > TAU
Stein et al. 2008 121 HAM-A Agomelatine > PP
Stein et al. 2014 233
234
HAM-A Agomelatine > PP
Escitalopram > PP
(Continued)
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blind assessors, dealing with incomplete outcome data), treatment quality (use of a
treatment manual, therapist training, check of treatment integrity), flexible versus fixed
dosage, mean age, percent female of total sample, percent comorbidity, and follow-up
length (if applicable). Dependent variables were classified as either primary (measures
of generalized anxiety) or secondary (measures of depression).
Control conditions were categorized as pill placebo (n = 43), waitlist (WL; n = 22),
psychological placebo (n = 10), or treatment as usual (TAU; n = 5), with one study
(Wetherell, Gatz, & Craske, 2003) including both a WL and psychological placebo
group. Psychological control conditions that were categorized as psychological placebo
included supportive therapy, affect-focused body psychotherapy, clinician-supported
therapy, nondirective therapy, nondirective supportive therapy, spiritually based inter-
vention, stress management education, discussion group, minimal contact (providing
Table 1. (Continued).
Authors Year N1 Primary measure(s)
Secondary measure
(s) Primary outcome2
Stein et al. 2017 270
278
HAM-A Agomelatine (10 mg) > PP
Agomelatine (25 mg) > PP
Titov et al. 2009 35 PSWQ PHQ-9 iCBT > WL
Titov et al. 2010 34 PSWQ iCBT > WL




PSWQ, STAI-T BDI-II Intolerance of uncertainty
therapy > WL
Metacognitive therapy > WL
Wetherell et al. 2003 39
36
BAI, HAM-A, PSWQ BDI, HAM-D CBT > WL
CBT > Psych PL
Wetherell et al. 2009 31 HAM-A, PSWQ BDI-II Modular psychotherapy > TAU




STAI-T BDI BT > WL
CBT > WL
CT > WL
Subconscious retraining > WL
Wu et al. 2011 210 HAM-A Duloxetine > PP
Zinbarg et al. 2007 18 BAI, PSWQ CBT > WL
Abbreviations: ACT: acceptance and commitment therapy; AR: applied relaxation; BDI: Beck Depression Inventory (Beck,
Ward, Mendelson, Mock, & Erbaugh, 1961); BDI-II: Beck Depression Inventory-II (Beck, Steer, & Brown, 1996); BT:
behavior therapy; CBT: cognitive behavior therapy; CT: cognitive therapy; HAM-A: Hamilton Anxiety Rating Scale;
HAM-D: Hamilton Depression Rating Scale (Hamilton, 1960); iCBT: internet cognitive behavior therapy; IPT: inter-
personal therapy; MADRS: Montgomery Asberg Depression Rating Scale (Montgomery & Asberg, 1979); MBSR:
mindfulness-based stress reduction; PP: pill placebo; PHQ-9 Patient Health Questionnaire—9 (Kroenke, Spitzer, &
Williams, 2001); PSWQ: Penn State Worry Questionnaire; PSWQ-A: Penn State Worry Questionnaire—Abbreviated;
Psych PL: psychological placebo; STAI-T: State-Trait Anxiety Inventory—Trait; TAU: treatment as usual; WL: waitlist.
Table 2. Primary and secondary outcome measures.
Outcome Measure
Primary Beck Anxiety Inventory
Hamilton Anxiety Rating Scale
Penn State Worry Questionnaire
Penn State Worry Questionnaire—Abbreviated
State-Trait Anxiety Inventory—Trait
Secondary Beck Depression Inventory
Beck Depression Inventory-II
Hamilton Depression Rating Scale
Montgomery-Asberg Depression Rating Scale
Patient Health Questionnaire—9
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assessments/brief support), and short-term psychodynamic psychotherapy. Control
conditions that study authors termed TAU were considered TAU for the analysis.
Control conditions in which participants did not receive any treatment for GAD
symptoms for a specified amount of time were considered WL.
Quantitative data analysis
The effect size for each study was computed using Hedges’ g (Rosenthal, 1991) in CMA.
Hedges’ g allows for correction for small sample sizes (Hedges & Olkin, 1985). When
the necessary data were available, Hedges’ g was calculated using means and standard
deviations. If means and standard deviations were not reported, we contacted the
authors to obtain these data. In cases that these values were not obtainable, Hedges’ g
was calculated using available data (least squares means, standard errors). If there were
not sufficient data to calculate Hedges’ g and authors could not be reached, the data
were not included in the final analyses. These controlled effect sizes may be interpreted
conservatively with Cohen’s convention of small (0.2), medium (0.5), and large (0.8)
effect sizes (Cohen, 1988). When there were multiple outcomes per domain, they were
combined according to Borenstein, Hedges, and Rothstein (2007).
The I2 statistic was used to measure heterogeneity. The I2 statistic describes the
percentage of variation due to heterogeneity, with 0% indicating no observed hetero-
geneity, 25% low, 50% moderate, and 75% high heterogeneity (Higgins, Thompson,
Deeks, & Altman, 2003). In addition, a test for significance of heterogeneity and the Q
value are reported. Because we expected considerable heterogeneity due to patient and
treatment variability, we used the random effects model in all analyses. For categorical
moderators, we reported p-values and between-group heterogeneity (Q) as recom-
mended by Hedges and Olkin (1985) and for continuous variables we used meta-
regression analyses, which is indicated by a slope and a p-value.
Study quality ratings
The quality of the studies that were included was rated using four items from the
Cochrane Risk of Bias Tool (Higgins & Green, 2011): (1) adequately random sequence
generation for group assignment, (2) concealment of allocation to conditions, (3) blind
assessors, and (4) dealing with incomplete outcome data.
Results
Characteristics and quality of included trials
Seventy-nine RCT including 11,002 participants met criteria for inclusion. Of the 79
included studies, 30 had low bias for sequence generation, 22 qualified for low bias for
allocation concealment, 66 qualified for low bias for blind assessors, and 39 qualified for
low bias for incomplete outcome data. Six studies met 0 study quality criteria, 27 studies
met one criterion, 21 studies met two criteria, 10 studies met three criteria, and 15
studies met all four criteria.
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Heterogeneity
A heterogeneity analysis was conducted to test the assumption that the effect sizes were
from a homogeneous sample (Hedges & Olkin, 1985). An analysis of all primary outcomes
on pretreatment to posttreatment time points revealed significant moderate heterogeneity
(I2 = 72.56, p < 0.001). This was also true when psychotherapy (I2 = 54.90, Q = 84.25,
p < 0.001) and medication studies (I2 = 54.26, Q = 163.72, p < 0.001) were considered
separately. Therefore, random effects analyses were most appropriate and moderator
analyses were justified. Studies and their effect sizes are presented in a forest plot (Figure 2).
Outliers were defined as studies whose effect size 95% confidence interval (CI) did
not overlap with the 95% CI of the pooled effect size of its psychotherapy or pharma-
cotherapy domain. When outliers were excluded, heterogeneity decreased in psy-
chotherapy (I2 = 37.84, p = 0.01) and pharmacotherapy (I2 = 40.14, p < 0.01)
domains. Excluding outliers did not significantly change primary outcomes for either
psychotherapy or medication domains, and therefore results excluding outliers are not
reported. The following analyses were conducted on all studies including outliers.
Efficacy on primary and secondary outcomes
Efficacy of psychotherapy versus control conditions on primary outcome measures
This analysis included 39 comparisons. Consistent with prediction, evidence-based
psychotherapies outperformed control conditions on primary outcome measures at
posttreatment with a medium to large effect size (g = 0.76, 95% CI: 0.61–0.91,
p < 0.001). At follow-ups, 12 comparisons showed that evidence-based psychotherapies
outperformed control conditions on primary outcome measures at follow-ups with a
small effect size (g = 0.27, 95% CI: 0.00–0.53, p = 0.05).
Within psychotherapy comparisons, pill placebo-controlled studies had the highest
effect size (n = 3, g = 1.44, 95% CI: 0.94–1.94, p < 0.001), followed by WL controls
(n = 22, g = 0.90, 95% CI: 0.73–1.08, p < 0.001), psychological placebo (n = 10, g = 0.47,
95% CI: 0.25–0.69, p < 0.001), and TAU (n = 5, g = 0.38, 95% CI: 0.05–0.71, p < 0.05; in
Wetherell et al., 2003, the psychological placebo and waitlist control group comparisons
were each included in this analysis).
Efficacy of psychotherapy versus control conditions on secondary outcome
measures
This analysis included 29 comparisons. Evidence-based psychotherapies outperformed
control conditions on secondary outcome measures at posttreatment with a medium
effect size (g = 0.64, 95% CI: 0.49–0.79, p < 0.001). At follow-ups, 8 comparisons showed
that evidence-based psychotherapies outperformed control conditions on secondary out-
come measures at follow-ups with a small effect size (g = 0.27, 95% CI: 0.06–0.49, p = 0.01).
Efficacy of pharmacotherapy versus control conditions on primary outcome
measures
This analysis included 43 comparisons. Consistent with prediction, pharmacotherapy
outperformed control conditions on primary outcome measures at posttreatment with a
small effect size (g = 0.38, 95% CI: 0.30–0.47, p < 0.001). There were no pharmacotherapy
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Study name Outcome Comparison Time point Hedges's g and 95% CI
Alaka, 2014 HAM-A Duloxetine vs. Pill Placebo Pre-Post
Aliyev, 2008 HAM-A Depakine-chrono vs. Pill Placebo Pre-Post
Allgulander, 2001 HAM-A Venlafaxine vs. Pill Placebo Pre-Post
Allgulander, 2004 HAM-A Sertaline vs. Pill Placebo Pre-Post
Bakhshani, 2007 Combined Combined Pre-Post
Ball, 2015 HAM-A Duloxetine vs. placebo Pre-Post
Barlow, 1992 Combined Combined Pre-Post
Bidzan, 2012 HAM-A Vortioextine vs. Pill Placebo Pre-Post
Bonne, 2003 Combined Homeopathic prep vs. Pill Placebo Pre-Post
Borkovec, 1987 Combined CT vs. NDT Pre-Post
Borkovec, 1993 Combined Combined Pre-Post
Bowman, 1997 Combined Self-examination therapy vs. WL Pre-Post
Brawman-Mintzer, 2006 HAM-A Sertaline vs. Pill Placebo Pre-Post
Brenes, 2015 Combined Telephone CBT vs. Telephone NDST Pre-Post
Butler, 1991 Combined Combined Pre-Post
Connor, 2002 HAM-A Kava Kava vs. Pill Placebo Pre-Post
Dahlin, 2016 Combined Internet acceptance-based BT v. WL Pre-Post
Darcis, 1995 HAM-A Hydroxyzine vs. Pill Placebo Pre-Post
Davidson, 1999 HAM-A Combined Pre-Post
Davidson, 2004 HAM-A Escitalopram vs. Pill Placebo Pre-Post
Davidson, 2008 HAM-A Duloxetine vs. Pill Placebo Pre-Post
Dugas, 2003 Combined Group CBT vs. WL Pre-Post
Dugas, 2010 Combined Combined Pre-Post
Durham, 1994 Combined Combined Pre-Post
Feltner, 2003 HAM-A Combined Pre-Post
Gelenberg, 2000 HAM-A Venlafaxine vs. Pill Placebo Pre-Post
Gommoll, 2015 HAM-A Combined Pre-Post
Hackett, 2003 HAM-A Combined Pre-Post
Hartford, 2007 HAM-A Combined Pre-Post
Hoge, 2013 Combined MBSR vs. Stress management Pre-Post
Hoyer, 2009 Combined Combined Pre-Post
Johnston, 2011 PSWQ Combined Pre-Post
Jones, 2016 PSWQ-A iCBT vs. WL Pre-Post
Kasper, 2009 HAM-A Combined Pre-Post
Koszycki, 2010 Combined CBT vs. SBI spiritual Pre-Post
Lader, 1998 HAM-A Combined Pre-Post
Ladouceur, 2000 Combined CBT vs. WL Pre-Post
Leichsenring, 2009 Combined CBT vs. STPP psychodynamic Pre-Post
Lenze, 2009 Combined Escitalopram vs. Pill Placebo Pre-Post
Levy Berg, 2009 BAI Affect-Focused Psychotherapy vs. TAU Pre-Post
Linden, 2005 HAM-A Combined Pre-Post
Llorca, 2002 HAM-A Hydroxyzine vs. Pill Placebo Pre-Post
Mahableshwarkar, 2014 HAM-A Combined Pre-Post
Mohlman, 2003a STAI-T Enhanced CBT vs. WL Pre-Post
Mohlman, 2003b BAI Standard CBT vs. WL Pre-Post
Moller, 2001 HAM-A Combined Pre-Post
Montgomery, 2008 HAM-A Pregbalin vs. Pill Placebo Pre-Post
Pande, 2003 HAM-A Combined Pre-Post
Park, 2014 Combined Combined Pre-Post
Paxling, 2011 Combined iCBT vs. WL Pre-Post
Pollack, 2001 HAM-A Paroxetine vs. Pill Placebo Pre-Post
Pollack, 2008a HAM-A Combined Pre-Post
Pollack, 2008b HAM-A Tiagbine vs. Pill Placebo Pre-Post
Pollack, 2008c HAM-A Tiagbine vs. Pill Placebo Pre-Post
Power, 1989 HAM-A Combined Pre-Post
Power, 1990 HAM-A Combined Pre-Post
Rezvan, 2008 PSWQ Combined Pre-Post
Rickels, 2000 HAM-A Venlafaxine vs. Pill Placebo Pre-Post
Rickels, 2003 HAM-A Combined Pre-Post
Rickels, 2005 HAM-A Combined Pre-Post
Robinson, 2010 PSWQ Combined Pre-Post
Roemer, 2008 PSWQ ACT vs. WL Pre-Post
Rothschild, 2012 HAM-A Vortioxetine vs. Pill Placebo Pre-Post
Sarris, 2013 Combined Kava Kava vs. Pill Placebo Pre-Post
Stanley, 1996 Combined CBT vs. Supportive Therapy Pre-Post
Stanley, 2003a Combined CBT vs. MCC psych placebo Pre-Post
Stanley, 2003b Combined CBT vs. TAU Pre-Post
Stanley, 2009 Combined CBT vs. TAU Pre-Post
Stein, 2008 HAM-A Agomelatine vs. Pill Placebo Pre-Post
Stein, 2014 HAM-A Combined Pre-Post
Stein, 2017 HAM-A Combined Pre-Post
Titov, 2009 PSWQ iCBT vs. WL Pre-Post
Titov, 2010 PSWQ iCBT vs. WL Pre-Post
Van der Heiden, 2012 Combined Combined Pre-Post
Wetherell, 2003 Combined Combined Pre-Post
Wetherell, 2009 Combined Modular Psychotherapy vs. TAU Pre-Post
White, 1992 STAI-T Combined Pre-Post
Wu, 2011 HAM-A Duloxetine vs. Pill Placebo Pre-Post
Zinbarg, 2007 Combined CBT vs. WL Pre-Post
-4.00 -2.00 0.00 2.00 4.00
Favours A Favours B
Figure 2. Effect sizes of treatments for GAD in adults compared with control conditions: Hedges' g.
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studies with data on follow-up measures of the primary outcome available. All included
medication comparisons used pill placebos as a control.
Efficacy of pharmacotherapy versus control conditions on secondary outcome
measures
This analysis included 11 comparisons. Pharmacotherapy outperformed control condi-
tions on secondary outcome measures at posttreatment with a medium effect size
(g = 0.59, 95% CI: 0.21–0.97, p < 0.01). There were no pharmacotherapy studies with
follow-up data of depression measures available.
Moderators
Moderator analyses were conducted on psychotherapy and pharmacotherapy separately.
Although outliers had minor effect on pooled effect size estimates, they were removed from
moderator analyses due to their substantial leverage and influence on regression results.
Mean age of the sample was a significant moderator of psychotherapy outcomes. A
lower mean age predicted a larger treatment effect size in psychotherapy (β = −0.013,
p < 0.05). This difference was also demonstrated when comparing psychotherapeutic
outcomes for adult and elderly populations categorically (Q = 5.16, df = 1, p < 0.05),
with studies involving non-elderly adult participants showing a larger effect size
(g = 0.87) than studies involving older adult participants (g = 0.47). Mean age was
not associated with outcome in medication studies (p > 0.05).
There was no significant relationship between effect size and treatment dose (number
of sessions or medication dosage), treatment quality, year of publication, fixed versus
flexible dose, percent comorbidity, percent female, or pretreatment severity (all p > 0.10).
Publication bias: “the file drawer problem”
Because nonsignificant studies tend not to be published, there may be a discrepancy in
results between the studies that are retrievable and all studies that have been conducted.
Unavailable negative results may lead to overestimate the true effect size. Rosenthal and
colleagues have termed this phenomenon “the file drawer problem” (Rosenthal, 1991).
Because pooled effect sizes in pharmacotherapy and psychotherapy domains differed
substantially, publication bias was examined separately in each. A funnel plot revealed
asymmetry in psychotherapy studies (Egger’s intercept = 1.93, p < 0.01; Figure 3), and
the Duval and Tweedie (2000) trim and fill procedure imputed 5 studies for an adjusted
effect size estimate of 0.66. A funnel plot in pharmacotherapy studies did not reveal
asymmetry according to Egger’s intercept and a trim and fill procedure did not impute
any studies or adjust the effect size estimate.
Discussion
Main findings
The current study provides an updated meta-analysis including 79 studies that showed
similar effect sizes to previous meta-analyses. The overall effect size of evidence-based
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psychotherapy for GAD on primary GAD outcomes (g = 0.76, n = 39) was comparable
to the previous meta-analysis on psychotherapy (g = 0.80, n = 31; Cuijpers et al., 2016).
Additionally, the effect size for medication for GAD (g = 0.38, n = 43) was comparable
to a previous meta-analysis for medication (d = 0.39, n = 21; Hidalgo et al., 2007).
While it may seem possible to draw the conclusion that psychotherapy has a larger
effect on GAD symptoms than pharmacotherapy, this is not supported for more than
one reason. First, the two treatment modalities use different control types. In the
current study, all pharmacotherapy trials used a pill placebo as a comparison, while
psychotherapy studies often had a waitlist control. Although in this analysis the three
pill placebo controlled psychotherapy studies had a higher effect size than waitlist
controlled studies, this is likely a fluke and underpowered, as a larger meta-analysis
of CBT for anxiety disorders showed that effects were large for waitlist conditions and
small to medium for pill placebo comparisons (n = 144 trials; Cuijpers et al., 2016). If a
pill placebo is a much more stringent control condition than WL, this would have
contributed to this apparent difference in effect size. Next, psychotherapy studies
showed evidence of publication bias. Finally, a network meta-analysis including head-
to-head treatment comparisons in addition to treatments versus control conditions
would provide a more comprehensive dataset for comparing treatments.
Most moderators did not show evidence of influence. This corroborates previous
conclusions (Schneider et al., 2015). However, younger age of the study sample was
associated with higher effect size in psychotherapy studies.
Implications
Some evidence suggests that patients strongly prefer psychological treatment to med-
ication, with one meta-analytic review showing a three-fold preference (McHugh,
Figure 3. Funnel plot for psychotherapy studies with imputed studies and adjusted effect size.
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Whitton, Peckham, Welge, & Otto, 2013). Because the efficacy appears to be at least
comparable, increased access to psychological treatment is necessary to provide suffi-
cient treatment to individuals with GAD.
Next, moderator analyses showed that mean age of the sample was a significant
moderator in the psychotherapy studies, such that younger mean age of the sample was
associated with more symptom improvement in psychotherapy. This difference was also
evident when comparing adult populations and elderly populations categorically.
Although this is not direct evidence that younger age was the cause of receptiveness
to psychotherapy, this is consistent with findings from a number of investigators that
treatments for anxiety disorders are not as effective for older people relative to younger
people (Gonçalves & Byrne, 2012; Gould et al., 2012; Hendriks et al., 2008; Pinquart &
Duberstein, 2007; Wetherell et al., 2013).
Limitations
Notably, although psychotherapy yielded larger effect sizes than medication, this meta-
analysis suggests that control type may contribute to this apparent difference. Publication
bias in psychotherapy studies might also contribute to the difference in psychotherapy and
medication effect sizes. Therefore, this meta-analysis indicates that although controlled
psychotherapy studies may have larger effect sizes than medication studies for GAD, the
methodologies in these studies are not equivalent enough to draw firm conclusions.
Studies that compare medication and psychotherapy side-by-side would be more infor-
mative to this end. Lastly, given the relatively small number of studies incorporating
follow-up measures of GAD symptoms (12 total included), as well as the variability of
follow-up times (2 weeks to 3 years), more evidence is necessary to draw conclusions about
psychotherapy and medication long-term outcomes following treatment.
Summary
This meta-analysis drew from 79 RCT with 11,002 participants to examine effects of
psychotherapy and pharmacological treatments for GAD. Both types of interventions
significantly improved both primary GAD outcomes and secondary depression out-
comes. The mean effect size for psychotherapy was g = 0.76 and for pharmacotherapy
was g = 0.38. However, control type (placebo v. TAU and WL) and publication bias cast
doubt on the validity of the comparison of the effect sizes. Age moderated the primary
GAD outcomes in psychotherapy, with younger age predicting better treatment
response.
Notes
1. N refers to the total number of participants included in each primary comparison (single
treatment group + single placebo), respectively, from pretreatment to posttreatment.
2. Direction of comparison refers to the group with the superior primary outcome at
posttreatment.
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